Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
Paul G. Richardson, Albert Oriol, Meral Beksaç, Anna Marina Liberati et autres
us, es, tr, it, no, gb, de, ca, fr, jp, ie, nl, pl, ru, ch, gr (code pays fourni par la source)
388 citations
The Lancet Oncology